MDxHealth SA (NASDAQ:MDXH) Short Interest Update

MDxHealth SA (NASDAQ:MDXH) saw a significant decrease in short interest during the month of June. As of June 15th, there was short interest totaling 106,013 shares, a decrease of 76.8% from the May 31st total of 457,830 shares. Based on an average trading volume of 796,277 shares, the short-interest ratio is presently 0.1 days. Currently, 0.2% of the company’s stock are sold short.

Institutional Investors Weigh In On MDxHealth

Institutional investors and hedge funds have recently modified their holdings of the company. Intesa Sanpaolo Wealth Management acquired a new position in MDxHealth in the 4th quarter worth approximately $36,000. Lido Advisors LLC acquired a new stake in MDxHealth during the 3rd quarter valued at approximately $48,000. GSA Capital Partners LLP acquired a new stake in MDxHealth during the 3rd quarter valued at approximately $48,000. Squarepoint Ops LLC purchased a new stake in shares of MDxHealth in the 4th quarter valued at $51,000. Finally, Jefferies Financial Group Inc. purchased a new stake in shares of MDxHealth in the 3rd quarter valued at $53,000.

Analyst Ratings Changes

Several research firms have issued reports on MDXH. Lake Street Capital cut their price target on shares of MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, May 14th. BTIG Research lowered their price objective on MDxHealth from $7.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. TD Cowen restated a “buy” rating and set a $1.50 target price (down from $7.00) on shares of MDxHealth in a research note on Thursday, May 14th. William Blair lowered MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Finally, Wall Street Zen cut MDxHealth from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $4.62.

MDxHealth Trading Down 6.1%

MDxHealth stock traded down $0.03 during mid-day trading on Friday, reaching $0.43. 1,276,300 shares of the company traded hands, compared to its average volume of 792,130. The firm’s fifty day moving average is $1.17 and its two-hundred day moving average is $2.51. MDxHealth has a fifty-two week low of $0.42 and a fifty-two week high of $5.33.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). MDxHealth had a negative return on equity of 1,078.01% and a negative net margin of 29.90%.The company had revenue of $23.90 million for the quarter, compared to analyst estimates of $30.89 million. Analysts predict that MDxHealth will post -0.6 EPS for the current year.

MDxHealth Company Profile

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.